Clinical Trials on Encephalitis, Arbovirus

Total 711 results

Valneva Austria GmbH

Completed

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Encephalitis

Philippines
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden
National Institute of Hygiene and Epidemiology,...
Ministry of Health, Vietnam; Ministry of Science and Technology, Vietnam

Completed

Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam (JECEVAX-3)

Japanese Encephalitis

Vietnam
National Institute of Hygiene and Epidemiology,...
Ministry of Health, Vietnam; Ministry of Science and Technology, Vietnam

Completed

Safety and Immunogenicity of JECEVAX in Young Children

Japanese Encephalitis

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Post-licensure Safety Study of IMOJEV® in Thailand

Japanese Encephalitis

Thailand
Valneva Austria GmbH

Completed

Safety Surveillance After Immunization With IXIARO

Japanese Encephalitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers

Japanese Encephalitis | Encephalitis

Thailand
Khon Kaen University

Unknown

Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children

Japanese Encephalitis

Thailand
University of Liverpool
B.P. Koirala Institute of Health Sciences; Kanti Children's Hospital

Completed

Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis

Japanese Encephalitis

Nepal
Valneva Austria GmbH

Withdrawn

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

Japanese Encephalitis

United Kingdom
Mennonite Christian Hospital

Unknown

Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan

Japanese Encephalitis
Medical University of Vienna
Austrian Science Fund (FWF)

Completed

Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients

Tick Borne Encephalitis

Austria
Pfizer

Completed

TBE Seropersistence up to 10 Years After First Booster in Adults

Tick-borne Encephalitis (TBE)

Poland
PATH

Completed

Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine

Encephalitis, Japanese B

Philippines
Medical University of Vienna
Valneva Austria GmbH

Unknown

Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.

Japanese Encephalitis Vaccine

Austria
Indian Institute of Science
Wellcome Trust; PATH; University of Liverpool; National Institute of Mental Health...

Completed

A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2

Japanese Encephalitis | Japanese Encephalitis Vaccine

India
Mahidol University

Completed

Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children (JE0153)

Encephalitis, Japanese B

Thailand
PATH
Quintiles, Inc.; Mahidol University; Research Institute for Tropical Medicine...

Completed

Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine

Encephalitis, Japanese B

Philippines
University Hospital, Limoges

Recruiting

Tick-borne Encephalitis Virus Research in Limousin (VITAL)

Tick-borne Encephalitis

France
University Hospital, Strasbourg, France

Recruiting

Prevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of Confirmed Pediatric Cases (TBE-KID)

Tick-borne Encephalitis

France
Valneva Austria GmbH

Completed

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
U.S. Army Medical Research and Development Command

Completed

Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine

Eastern Equine Encephalitis

United States
Pfizer

Completed

Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

Encephalitis, Tick-borne

Belgium
Pfizer

Completed

Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

Encephalitis, Tick-borne

Austria
Pfizer

Completed

Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

Encephalitis, Tick-borne

Belgium
Pfizer

Completed

Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years

Tick-borne Encephalitis

Poland
Pfizer

Completed

Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

Encephalitis, Tick-Borne

Poland
Novartis
Novartis Vaccines

Completed

Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children

Encephalitis, Tick-Borne

Germany
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Purified Inactivated Japanese Encephalitis Vaccine

Japanese Encephalitis Virus Disease

China
University of Liverpool

Completed

Flavivirus Cross-priming Potential of IMOJEV (FlaviPrime)

Japanese Encephalitis

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for IMOJEV® in Republic of Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company
National Institute of Hygiene and Epidemiology, Vietnam

Completed

Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

Japanese Encephalitis

Vietnam
PATH
Mahidol University; Ministry of Health of Sri Lanka; Quintiles Singapore

Completed

Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age (JEV03)

Japanese Encephalitis

Sri Lanka
PATH

Completed

Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine

Japanese Encephalitis

Bangladesh
Sanofi Pasteur, a Sanofi Company

Completed

Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers

Japanese Encephalitis | Encephalitis

Thailand, Philippines
Valneva Austria GmbH

Completed

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Japanese Encephalitis

Germany, Austria
Chulalongkorn University
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

Japanese Encephalitis
Valneva Austria GmbH

Completed

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Boryung Pharmaceutical Co., Ltd
Samsung Medical Center; Seoul National University Hospital; Gachon University... and other collaborators

Completed

Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea

Japanese Encephalitis

Korea, Republic of
Sanofi

Completed

Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age

Japanese Encephalitis

India
Sanofi

Completed

A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

Japanese Encephalitis | Encephalitis

Australia
Valneva Austria GmbH

Completed

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

Japanese Encephalitis

Germany, Austria
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers

Japanese Encephalitis | Japanese Encephalitis Virus Disease

Korea, Republic of
PATH

Completed

Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine

Japanese Encephalitis

Sri Lanka
Valneva Austria GmbH

Completed

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Japanese Encephalitis

Australia, United States, Germany
National Institute of Hygiene and Epidemiology,...
Ministry of Health, Vietnam; Ministry of Science and Technology, Vietnam

Completed

Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age (JECEVAX-2B)

Japanese Encephalitis

Vietnam
Boryung Pharmaceutical Co., Ltd

Completed

Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj (BR-JELITE)

Japanese Encephalitis

Korea, Republic of
Jiangsu Province Centers for Disease Control and...
Shandong Hengye Biotech Co., Ltd.

Completed

A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants

Encephalitis

China

3

Subscribe